Bristol Myers Squibb’s first-in-class myosin modulator mavacamten (brand name Camzyos) has been approved by the European Commission for the treatment of obstructive hypertrophic cardiomyopathy in all countries which are part of the European Union.
This study looked at 4893 patients with hypertrophic cardiomyopathy treated at 7 different European HCM centers between 1980 and 2013. Although the statistics improved for those who were treated more recently, this study makes it clear that there is still much room for improvement in risk stratification and treatment for patients with HCM.